CY1122122T1 - Υδατικο οφθαλμικο διαλυμα και μεθοδος για τη θεραπευτικη αγωγη συνδρομου ξηρου οφθαλμου - Google Patents

Υδατικο οφθαλμικο διαλυμα και μεθοδος για τη θεραπευτικη αγωγη συνδρομου ξηρου οφθαλμου

Info

Publication number
CY1122122T1
CY1122122T1 CY20191100965T CY191100965T CY1122122T1 CY 1122122 T1 CY1122122 T1 CY 1122122T1 CY 20191100965 T CY20191100965 T CY 20191100965T CY 191100965 T CY191100965 T CY 191100965T CY 1122122 T1 CY1122122 T1 CY 1122122T1
Authority
CY
Cyprus
Prior art keywords
dry eye
solution
ophtic
aqueous
eye syndrome
Prior art date
Application number
CY20191100965T
Other languages
English (en)
Inventor
Martin Prinz
Original Assignee
Croma-Pharma Gesellschaft M.B.H.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50693490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122122(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Croma-Pharma Gesellschaft M.B.H. filed Critical Croma-Pharma Gesellschaft M.B.H.
Publication of CY1122122T1 publication Critical patent/CY1122122T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
    • B65D65/38—Packaging materials of special type or form
    • B65D65/40—Applications of laminates for particular packaging purposes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Η παρούσα εφεύρεση ασχολείται με ένα στείρο υδατικό οφθαλμικό διάλυμα το οποίο αποτελείται από περίπου 0.05% έως περίπου 0.5% (β/β) Ν-(Ν-ακετυλκυστεϊνυλ-)χιτοζάνη ή ένα φαρμακευτικώς αποδεκτό άλας αυτής σε ένα διάλυμα φορέα, όπου η Ν-(Ν-ακετυλκυστεϊνυλ-)χιτοζάνη έχει μια περιεκτικότητα σε ελεύθερες ομάδες θειόλης σε μια ποσότητα από 80 μmol/g πολυμερούς έως 280 μmol/g πολυμερούς. Η εφεύρεση ασχολείται επίσης με έναν περιέκτη που περιέχει το εν λόγω οφθαλμικό διάλυμα καθώς επίσης τη χρήση αυτού στην πρόληψη ή θεραπευτική αγωγή του συνδρόμου ξηρού οφθαλμού ή σημαδιών ή/και συμπτωμάτων ξηροφθαλμίας.
CY20191100965T 2014-05-07 2019-09-16 Υδατικο οφθαλμικο διαλυμα και μεθοδος για τη θεραπευτικη αγωγη συνδρομου ξηρου οφθαλμου CY1122122T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14167381 2014-05-07
PCT/EP2015/059674 WO2015169728A1 (en) 2014-05-07 2015-05-04 Aqueous ophthalmic solution and method for treating dry eye syndrome

Publications (1)

Publication Number Publication Date
CY1122122T1 true CY1122122T1 (el) 2020-11-25

Family

ID=50693490

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100965T CY1122122T1 (el) 2014-05-07 2019-09-16 Υδατικο οφθαλμικο διαλυμα και μεθοδος για τη θεραπευτικη αγωγη συνδρομου ξηρου οφθαλμου

Country Status (27)

Country Link
US (2) US10342759B2 (el)
EP (1) EP3139903B1 (el)
JP (1) JP6639480B2 (el)
KR (1) KR102378391B1 (el)
CN (1) CN106456536B (el)
AR (1) AR100334A1 (el)
AU (1) AU2015257874B2 (el)
BR (1) BR112016024454B1 (el)
CA (1) CA2947065C (el)
CL (1) CL2016002815A1 (el)
CY (1) CY1122122T1 (el)
DK (1) DK3139903T3 (el)
ES (1) ES2747808T3 (el)
HR (1) HRP20191667T1 (el)
HU (1) HUE046425T2 (el)
IL (1) IL248804B (el)
LT (1) LT3139903T (el)
MA (1) MA39767B1 (el)
ME (1) ME03505B (el)
MX (1) MX2016013710A (el)
PL (1) PL3139903T3 (el)
PT (1) PT3139903T (el)
RS (1) RS59383B1 (el)
RU (1) RU2688935C2 (el)
SG (1) SG11201608402WA (el)
SI (1) SI3139903T1 (el)
WO (1) WO2015169728A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033250B1 (ru) 2014-05-07 2019-09-30 Бристол-Майерс Сквибб Компани Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
FR3039765B1 (fr) * 2015-08-07 2018-08-24 Oreal Procede cosmetique de traitement des matieres keratiniques
AU2016332966A1 (en) * 2015-09-28 2018-04-26 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US10813943B2 (en) 2015-10-30 2020-10-27 Croma-Pharma Gesellschaft M.B.H. Therapeutic use of a sterile aqueous ophthalmic solution
WO2017072236A1 (en) * 2015-10-30 2017-05-04 Croma-Pharma Gesellschaft M.B.H. Therapeutic use of a sterile aqueous ophthalmic solution
JP7154764B2 (ja) * 2015-12-22 2022-10-18 日油株式会社 涙液油層安定化剤およびこれを含有する点眼剤
MX2018012390A (es) 2016-04-14 2019-07-04 Azura Ophthalmics Ltd Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio.
ES2650981B2 (es) * 2016-07-20 2018-05-04 Ocupharm Diagnostics, Sl Preparación y uso de un extracto de Artemia salina para tratar la superficie ocular
CA3034604C (en) * 2016-10-19 2021-03-09 Novartis Ag Hydrophilic copolymer with pendant thiol groups
AR110125A1 (es) 2016-11-07 2019-02-27 Croma Pharma Ges M B H Compuestos poliméricos que liberan sulfuro de hidrógeno
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
CN110719775A (zh) * 2017-03-29 2020-01-21 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌的药剂
EP3618803A1 (en) 2017-05-03 2020-03-11 Croma-Pharma GmbH Sterile aqueous ophthalmic solution containing n-(n-acetylcysteinyl)-chitosan for treating non-infectious corneal disorders
KR20220163519A (ko) * 2018-02-28 2022-12-09 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
CN109793707B (zh) * 2019-01-30 2022-04-08 温州医科大学 一种透明质酸—n-乙酰半胱氨酸—壳聚糖滴眼液及其制备方法
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물
WO2021101883A1 (en) * 2019-11-18 2021-05-27 Pamel Gregory J Chitosan containing compositions and methods relating to same
CA3166357A1 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
CN114848670B (zh) * 2022-05-26 2023-06-02 青岛博益特生物材料股份有限公司 一种滴眼液及其制备方法
WO2024151787A1 (en) * 2023-01-11 2024-07-18 MAM Holdings of West Florida, L.L.C. Methods and compositions for treating dry eye, tear hyperosmolarity, and other ocular conditions
US20240330778A1 (en) * 2023-04-03 2024-10-03 Halliburton Energy Services, Inc. Borehole holdup prediction using machine learning and pulsed neutron logging tool data

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
FR2692582B1 (fr) 1992-06-18 1998-09-18 Flamel Tech Sa Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux.
EP0820274A1 (en) * 1995-04-04 1998-01-28 Otsuka Pharmaceutical Co., Ltd. Package holding a procaterol hydrochloride aqueous solution formulation, and a procaterol hydrochloride aqueous solution formulation
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
AT406054B (de) 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
JP2000302803A (ja) 1999-04-22 2000-10-31 Noevir Co Ltd アミノ酸及びペプチドにより遊離アミノ基が選択的に置換され、実質的に水酸基の置換のない部分脱アセチル化キチン・キトサン誘導体、及びその製造方法
ITRM20010438A1 (it) * 2001-07-23 2003-01-23 Farmigea Spa Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
WO2008052037A2 (en) * 2006-10-24 2008-05-02 Alcon Research, Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
AU2007336692B2 (en) * 2006-12-22 2013-12-12 Croma-Pharma Gesellschaft M.B.H. Use of polymers
CA2676919C (en) 2007-01-31 2013-01-29 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
US9452592B2 (en) 2007-08-28 2016-09-27 Cryovac, Inc. Multilayer film having an active oxygen barrier layer with radiation enhanced active barrier properties
AU2009240512B2 (en) 2008-04-24 2014-07-10 Medtronic, Inc. Protective gel based on chitosan and oxidized polysaccharide
EP2313104B2 (en) 2008-04-24 2020-08-26 Medtronic, Inc Thiolated chitosan gel
US8530632B2 (en) 2008-04-24 2013-09-10 Medtronic Xomed, Inc. Chitosan-containing protective composition

Also Published As

Publication number Publication date
EP3139903B1 (en) 2019-07-03
CL2016002815A1 (es) 2017-05-12
DK3139903T3 (da) 2019-09-09
RU2016143341A3 (el) 2018-12-25
JP6639480B2 (ja) 2020-02-05
KR102378391B1 (ko) 2022-03-24
IL248804A0 (en) 2017-01-31
LT3139903T (lt) 2019-09-10
PT3139903T (pt) 2019-10-24
IL248804B (en) 2020-05-31
ES2747808T3 (es) 2020-03-11
KR20170030471A (ko) 2017-03-17
PL3139903T3 (pl) 2019-12-31
MA39767B1 (fr) 2019-10-31
JP2017514916A (ja) 2017-06-08
CN106456536B (zh) 2020-05-12
WO2015169728A1 (en) 2015-11-12
AR100334A1 (es) 2016-09-28
AU2015257874A1 (en) 2016-10-20
MA39767A (fr) 2015-11-12
ME03505B (me) 2020-04-20
US20190269613A1 (en) 2019-09-05
CA2947065A1 (en) 2015-11-12
BR112016024454A2 (pt) 2017-08-15
SI3139903T1 (sl) 2019-10-30
US10342759B2 (en) 2019-07-09
AU2015257874B2 (en) 2019-11-28
HUE046425T2 (hu) 2020-02-28
EP3139903A1 (en) 2017-03-15
RU2688935C2 (ru) 2019-05-23
US10653620B2 (en) 2020-05-19
RU2016143341A (ru) 2018-06-07
BR112016024454A8 (pt) 2021-06-29
BR112016024454B1 (pt) 2023-03-07
US20170224614A1 (en) 2017-08-10
CA2947065C (en) 2022-04-19
SG11201608402WA (en) 2016-11-29
RS59383B1 (sr) 2019-11-29
HRP20191667T1 (hr) 2019-12-13
MX2016013710A (es) 2017-03-31
CN106456536A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
CY1122122T1 (el) Υδατικο οφθαλμικο διαλυμα και μεθοδος για τη θεραπευτικη αγωγη συνδρομου ξηρου οφθαλμου
CY1124675T1 (el) Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1124596T1 (el) Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση
CY1120125T1 (el) Διαδικασια για την παραγωγη ενος ενεσιμου διαλυματος νοραδρεναλινης σε σταθερη χαμηλη συγκεντρωση
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
CY1123947T1 (el) Βελτιστοποιημενος υποκινητης rpe65 και βελτιστοποιημενες κωδικοποιητικες αλληλουχιες
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
EA201791333A1 (ru) Производные глюкагона с улучшенной стабильностью
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
CY1122457T1 (el) Μη πτητικες οφθαλμικες συνθεσεις, ειδικες για τη θεραπεια της ξηροφθαλμιας
CY1122374T1 (el) Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
AR099680A1 (es) Muteínas mejoradas de factor viii de coagulación
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular
MX2018004779A (es) Uso terapeutico de una solucion oftalmica acuosa esteril.
CL2021000858A1 (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento